The latest perspectives of small molecules FMS kinase inhibitors.

[1]  T. Al‐Tel,et al.  Complexity‐to‐Diversity and Pseudo‐Natural Product Strategies as Powerful Platforms for Deciphering Next‐Generation Therapeutics , 2023, ChemMedChem.

[2]  A. Faried,et al.  Emerging hallmark of gliomas microenvironment in evading immunity: a basic concept , 2023, The Egyptian Journal of Neurology, Psychiatry and Neurosurgery.

[3]  J. Pollard,et al.  A timeline of tumour-associated macrophage biology , 2023, Nature Reviews Cancer.

[4]  E. Martínez-Cáceres,et al.  Regulatory cells and the effect of cancer immunotherapy , 2023, Molecular Cancer.

[5]  Sanyin Zhang,et al.  Artificial intelligence for drug discovery: Resources, methods, and applications , 2023, Molecular therapy. Nucleic acids.

[6]  D. Cibula,et al.  Targeting tumor-associated macrophages for successful immunotherapy of ovarian carcinoma , 2023, Journal for ImmunoTherapy of Cancer.

[7]  Yue Zhu,et al.  IL‐33‐ST2 pathway regulates AECII transdifferentiation by targeting alveolar macrophage in a bronchopulmonary dysplasia mouse model , 2022, Journal of cellular and molecular medicine.

[8]  E. Adriaenssens,et al.  Macrophage-Colony-Stimulating Factor Receptor Enhances Prostate Cancer Cell Growth and Aggressiveness In Vitro and In Vivo and Increases Osteopontin Expression , 2022, International journal of molecular sciences.

[9]  Alanna G. Spiteri,et al.  Putting PLX5622 into perspective: microglia in central nervous system viral infection , 2022, Neural regeneration research.

[10]  J. Jee,et al.  Antitumor activity of a pexidartinib bioisostere inhibiting CSF1 production and CSF1R kinase activity in human hepatocellular carcinoma. , 2022, Chemico-biological interactions.

[11]  Heng Li,et al.  Targeting CSF-1R represents an effective strategy in modulating inflammatory diseases. , 2022, Pharmacological research.

[12]  Bin Shen,et al.  Discovery of a CSF-1R inhibitor and PET tracer for imaging of microglia and macrophages in the brain. , 2022, Nuclear medicine and biology.

[13]  N. Matsumura,et al.  Dynamic host immunity and PD-L1/PD-1 blockade efficacy: developments after “IFN-γ from lymphocytes induces PD-L1 expression and promotes progression of ovarian cancer” , 2022, British Journal of Cancer.

[14]  Q. Liu,et al.  Discovery of Pyrrolo[2,3-d]pyrimidine derivatives as potent and selective colony stimulating factor 1 receptor kinase inhibitors. , 2022, European journal of medicinal chemistry.

[15]  Min-Hee Yi,et al.  Chemogenetic and Optogenetic Manipulations of Microglia in Chronic Pain , 2022, Neuroscience Bulletin.

[16]  Stacie L. Bulfer,et al.  Discovery of Acyl Ureas as Highly Selective Small Molecule CSF1R Kinase Inhibitors. , 2022, Bioorganic & medicinal chemistry letters.

[17]  Stacie L. Bulfer,et al.  Discovery of vimseltinib (DCC-3014), a highly selective CSF1R switch-control kinase inhibitor, in clinical development for the treatment of Tenosynovial Giant Cell Tumor (TGCT). , 2022, Bioorganic & medicinal chemistry letters.

[18]  Amy McKee,et al.  Decoding kinase-adverse event associations for small molecule kinase inhibitors , 2022, Nature Communications.

[19]  L. Pasquini,et al.  Microglia depletion as a therapeutic strategy: friend or foe in multiple sclerosis models? , 2022, Neural regeneration research.

[20]  A. Sierra,et al.  Microglia and meningeal macrophages depletion delays the onset of experimental autoimmune encephalomyelitis , 2022, bioRxiv.

[21]  L. Deng,et al.  Regulated macrophage immune microenvironment in 3D printed scaffolds for bone tumor postoperative treatment , 2022, Bioactive materials.

[22]  S. Markidis,et al.  Artificial intelligence in virtual screening: models versus experiments. , 2022, Drug discovery today.

[23]  Z. Wszolek,et al.  Inhibition of colony stimulating factor-1 receptor (CSF-1R) as a potential therapeutic strategy for neurodegenerative diseases: opportunities and challenges , 2022, Cellular and Molecular Life Sciences.

[24]  Michael V. Gonzalez,et al.  CSF-1 maintains pathogenic but not homeostatic myeloid cells in the central nervous system during autoimmune neuroinflammation , 2022, Proceedings of the National Academy of Sciences of the United States of America.

[25]  I. Campbell,et al.  PLX5622 Reduces Disease Severity in Lethal CNS Infection by Off-Target Inhibition of Peripheral Inflammatory Monocyte Production , 2022, Frontiers in Immunology.

[26]  Takashi Kato,et al.  [11C]NCGG401, a novel PET ligand for imaging of colony stimulating factor 1 receptors. , 2022, Bioorganic & medicinal chemistry letters.

[27]  R. Martini,et al.  Early targeting of endoneurial macrophages alleviates the neuropathy and affects abnormal Schwann cell differentiation in a mouse model of Charcot‐Marie‐Tooth 1A , 2022, Glia.

[28]  Wei Wang,et al.  The preventive effects of colony‐stimulating factor 1 receptor (CSF‐1R) inhibition on bladder outlet obstruction induced remodeling , 2022, Neurourology and urodynamics.

[29]  Jeonghyun Choi,et al.  Neurodegenerative effect of DAPK1 after cerebral hypoxia-ischemia is associated with its post-transcriptional and signal transduction regulations: A systematic review and meta-analysis , 2022, Ageing Research Reviews.

[30]  C. Piperi,et al.  Targeting Options of Tumor-Associated Macrophages (TAM) Activity in Gliomas , 2022, Current neuropharmacology.

[31]  G. El-Sokkary,et al.  Acceleration of slow autophagy flux induced by arabinofuranosyl cytidine improves its antileukemic effectiveness in M-NFS-60 cells , 2022, Turkish journal of biology = Turk biyoloji dergisi.

[32]  M. Schäfers,et al.  The Colony Stimulating Factor-1 Receptor (CSF-1R)-Mediated Regulation of Microglia/Macrophages as a Target for Neurological Disorders (Glioma, Stroke) , 2021, Frontiers in Immunology.

[33]  O. Engkvist,et al.  Has Artificial Intelligence Impacted Drug Discovery? , 2021, Methods in molecular biology.

[34]  Lihong Hu,et al.  Discovery of (Z)-1-(3-((1H-Pyrrol-2-yl)methylene)-2-oxoindolin-6-yl)-3-(isoxazol-3-yl)urea Derivatives as Novel and Orally Highly Effective CSF-1R Inhibitors for Potential Colorectal Cancer Immunotherapy. , 2021, Journal of medicinal chemistry.

[35]  M. Shah,et al.  A comprehensive study on artificial intelligence and machine learning in drug discovery and drug development , 2021, Intelligent Medicine.

[36]  G. Shapiro,et al.  Results from Phase I Extension Study Assessing Pexidartinib Treatment in Six Cohorts with Solid Tumors including TGCT, and Abnormal CSF1 Transcripts in TGCT , 2021, Clinical Cancer Research.

[37]  H. Hsieh,et al.  Discovery of BPR1R024, an Orally Active and Selective CSF1R Inhibitor that Exhibits Antitumor and Immunomodulatory Activity in a Murine Colon Tumor Model. , 2021, Journal of medicinal chemistry.

[38]  Yanfei Liu,et al.  The Expanding Role of Pyridine and Dihydropyridine Scaffolds in Drug Design , 2021, Drug design, development and therapy.

[39]  N. Boechat,et al.  Pyrroles as Privileged Scaffolds in the Search for New Potential HIV Inhibitors , 2021, Pharmaceuticals.

[40]  E. Roh,et al.  Development of New Meridianin/Leucettine-Derived Hybrid Small Molecules as Nanomolar Multi-Kinase Inhibitors with Antitumor Activity , 2021, Biomedicines.

[41]  J. Jee,et al.  Novel Pyridine Bioisostere of Cabozantinib as a Potent c-Met Kinase Inhibitor: Synthesis and Anti-Tumor Activity against Hepatocellular Carcinoma , 2021, International journal of molecular sciences.

[42]  Xiangxiang Zhou,et al.  Targeting the tumor microenvironment in B-cell lymphoma: challenges and opportunities , 2021, Journal of Hematology & Oncology.

[43]  Benjamin A. Logsdon,et al.  Comprehensive Evaluation of the 5XFAD Mouse Model for Preclinical Testing Applications: A MODEL-AD Study , 2021, Frontiers in Aging Neuroscience.

[44]  Hui-jiao Chen,et al.  The roles of MCP-1/CCR2 mediated macrophage recruitment and polarization in bladder outlet obstruction (BOO) induced bladder remodeling. , 2021, International immunopharmacology.

[45]  Abul Bashar Mir Md. Khademul Islam,et al.  Fenugreek steroidal saponins hinder osteoclastogenic bone resorption by targeting CSF-1R which diminishes the RANKL/OPG ratio. , 2021, International journal of biological macromolecules.

[46]  A. Windhorst,et al.  BLZ945 derivatives for PET imaging of colony stimulating factor-1 receptors in the brain. , 2021, Nuclear medicine and biology.

[47]  Dimitris Samaras,et al.  Artificial Intelligence in Drug Discovery: Applications and Techniques , 2021, Briefings Bioinform..

[48]  Chia‐Chi Lin.  Clinical Development of Colony-Stimulating Factor 1 Receptor (CSF1R) Inhibitors. , 2021, Journal of immunotherapy and precision oncology.

[49]  F. Pan,et al.  Involvement of Macrophages and Spinal Microglia in Osteoarthritis Pain , 2021, Current Rheumatology Reports.

[50]  L. Dirix,et al.  A phase 1a/1b trial of CSF-1R inhibitor LY3022855 in combination with durvalumab or tremelimumab in patients with advanced solid tumors , 2021, Investigational New Drugs.

[51]  J. Ferlay,et al.  Cancer statistics for the year 2020: An overview , 2021, International journal of cancer.

[52]  Zhihong Wu,et al.  Variants Affecting the C-Terminal of CSF1R Cause Congenital Vertebral Malformation Through a Gain-of-Function Mechanism , 2021, Frontiers in Cell and Developmental Biology.

[53]  R. Carvajal,et al.  LY3022855, an anti–colony stimulating factor-1 receptor (CSF-1R) monoclonal antibody, in patients with advanced solid tumors refractory to standard therapy: phase 1 dose-escalation trial , 2021, Investigational New Drugs.

[54]  Jina Kim,et al.  Discovery of potent colony-stimulating factor 1 receptor inhibitors by replacement of hinge-binder moieties. , 2021, European journal of medicinal chemistry.

[55]  Jianming Xu.  Current treatments and future potential of surufatinib in neuroendocrine tumors (NETs) , 2021, Therapeutic advances in medical oncology.

[56]  C. Brotherton-Pleiss,et al.  Discovery of Novel Azetidine Amides as Potent Small-Molecule STAT3 Inhibitors , 2020, Journal of medicinal chemistry.

[57]  Zhi Peng,et al.  Surufatinib plus toripalimab in patients with advanced solid tumors: a single-arm, open-label, phase 1 trial , 2020, Journal of Cancer Research and Clinical Oncology.

[58]  R. Patani,et al.  The microglial component of amyotrophic lateral sclerosis , 2020, Brain : a journal of neurology.

[59]  G. Simone,et al.  Molecular Bases of VEGFR-2-Mediated Physiological Function and Pathological Role , 2020, Frontiers in Cell and Developmental Biology.

[60]  D. Chen,et al.  Therapeutic Targeting of Retinal Immune Microenvironment With CSF-1 Receptor Antibody Promotes Visual Function Recovery After Ischemic Optic Neuropathy , 2020, Frontiers in Immunology.

[61]  R. B. Bakr,et al.  Pyrimidine and fused pyrimidine derivatives as promising protein kinase inhibitors for cancer treatment , 2020 .

[62]  Shimin Hu,et al.  CSF‐1R inhibition disrupts the dialog between leukaemia cells and macrophages and delays leukaemia progression , 2020, Journal of cellular and molecular medicine.

[63]  M. Grce,et al.  New Approaches for the Treatment of Chronic Graft-Versus-Host Disease: Current Status and Future Directions , 2020, Frontiers in Immunology.

[64]  M. Gordon,et al.  Evaluation of Potential Drug‐Drug Interaction Risk of Pexidartinib With Substrates of Cytochrome P450 and P‐Glycoprotein , 2020, Journal of clinical pharmacology.

[65]  T. Doman,et al.  Immunomodulatory Activity of a Colony-stimulating Factor-1 Receptor Inhibitor in Patients with Advanced Refractory Breast or Prostate Cancer: A Phase I Study , 2020, Clinical Cancer Research.

[66]  H. Kitaura,et al.  Anti-c-fms Antibody Prevents Osteoclast Formation and Bone Resorption in Co-Culture of Osteoblasts and Osteoclast Precursors In Vitro and in Ovariectomized Mice , 2020, International journal of molecular sciences.

[67]  Kyung-Hyun Park-Min,et al.  The M-CSF receptor in osteoclasts and beyond , 2020, Experimental & Molecular Medicine.

[68]  Kyung-Sook Chung,et al.  Diarylurea derivatives comprising 2,4-diarylpyrimidines: Discovery of novel potential anticancer agents via combined failed-ligands repurposing and molecular hybridization approaches. , 2020, Bioorganic chemistry.

[69]  Nianguang Li,et al.  Small-molecule Fms-like Tyrosine Kinase 3 Inhibitors: An Attractive and Efficient Method for the Treatment of Acute Myeloid Leukemia. , 2020, Journal of medicinal chemistry.

[70]  T. E. Schultz,et al.  Pexidartinib, a Novel Small Molecule CSF-1R Inhibitor in Use for Tenosynovial Giant Cell Tumor: A Systematic Review of Pre-Clinical and Clinical Development , 2020, Drug design, development and therapy.

[71]  Nicholas J. Slipek,et al.  PLX3397 treatment inhibits constitutive CSF1R-induced oncogenic ERK signaling, reduces tumor growth, and metastatic burden in osteosarcoma. , 2020, Bone.

[72]  M. Kipp,et al.  The Cuprizone Model: Dos and Do Nots , 2020, Cells.

[73]  Lianhong Li,et al.  PD-1/PD-L1 pathway: current researches in cancer. , 2020, American journal of cancer research.

[74]  K. Kang,et al.  Evaluation of the Neuroprotective Effect of Microglial Depletion by CSF-1R Inhibition in a Parkinson’s Animal Model , 2020, Molecular imaging and biology.

[75]  T. Hata,et al.  Pharmacological Properties of JTE-952, an Orally Available and Selective Colony Stimulating Factor 1 Receptor Kinase Inhibitor. , 2020, Biological & pharmaceutical bulletin.

[76]  L. Arendt-Nielsen,et al.  Serum Inflammatory Markers in Patients With Knee Osteoarthritis , 2020, The Clinical journal of pain.

[77]  Lin-jiang Tong,et al.  Novel Class of Colony-Stimulating Factor 1 Receptor Kinase Inhibitors Based on an o-Aminopyridyl Alkynyl Scaffold as Potential Treatment for Inflammatory Disorders. , 2020, Journal of medicinal chemistry.

[78]  L. Legnani,et al.  Pyridine and Pyrimidine Derivatives as Privileged Scaffolds in Biologically Active Agents. , 2020, Current medicinal chemistry.

[79]  Long-Jun Wu,et al.  Pharmacological inhibition of CSF1R by GW2580 reduces microglial proliferation and is protective against neuroinflammation and dopaminergic neurodegeneration , 2020, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[80]  Qiang Xu,et al.  Targeting SHP2 as a promising strategy for cancer immunotherapy. , 2019, Pharmacological research.

[81]  N. Naka,et al.  Phase I study of TAS-115, a novel oral multi-kinase inhibitor, in patients with advanced solid tumors , 2019, Investigational New Drugs.

[82]  Ki Duk Park,et al.  Reprofiling of pyrimidine-based DAPK1/CSF1R dual inhibitors: identification of 2,5-diamino-4-pyrimidinol derivatives as novel potential anticancer lead compounds , 2019, Journal of enzyme inhibition and medicinal chemistry.

[83]  P. Mcgonigle,et al.  The pharmacology and therapeutic applications of monoclonal antibodies , 2019, Pharmacology research & perspectives.

[84]  S. Plevy,et al.  The CSF-1-receptor inhibitor, JNJ-40346527 (PRV-6527), reduced inflammatory macrophage recruitment to the intestinal mucosa and suppressed murine T cell mediated colitis , 2019, PloS one.

[85]  Yunyu Zhang,et al.  Modulation of Microglia by Voluntary Exercise or CSF1R Inhibition Prevents Age-Related Loss of Functional Motor Units. , 2019, Cell reports.

[86]  Yvette N. Lamb.  Pexidartinib: First Approval , 2019, Drugs.

[87]  Tobias C. Wood,et al.  CSF1R inhibitor JNJ-40346527 attenuates microglial proliferation and neurodegeneration in P301S mice , 2019, Brain : a journal of neurology.

[88]  Yi Chen,et al.  Preclinical evaluation of 3D185, a novel potent inhibitor of FGFR1/2/3 and CSF-1R, in FGFR-dependent and macrophage-dominant cancer models , 2019, Journal of Experimental & Clinical Cancer Research.

[89]  Chao Zhang,et al.  Sustained microglial depletion with CSF1R inhibitor impairs parenchymal plaque development in an Alzheimer’s disease model , 2019, Nature Communications.

[90]  J. Bennett,et al.  Concentration-dependent effects of CSF1R inhibitors on oligodendrocyte progenitor cells ex vivo and in vivo , 2019, Experimental Neurology.

[91]  Y. Zhang,et al.  Generation of Oligodendrocyte Progenitor Cells From Mouse Bone Marrow Cells , 2019, Front. Cell. Neurosci..

[92]  K. Mortezaee,et al.  Effect of the CSF1R inhibitor PLX3397 on remyelination of corpus callosum in a cuprizone‐induced demyelination mouse model , 2019, Journal of cellular biochemistry.

[93]  Kiran Boppana,et al.  Identification, synthesis and evaluation of CSF1R inhibitors using fragment based drug design , 2019, Comput. Biol. Chem..

[94]  E. Solary,et al.  Dynamic gene regulation by nuclear colony-stimulating factor 1 receptor in human monocytes and macrophages , 2019, Nature Communications.

[95]  K. Freude,et al.  Implications of Microglia in Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. , 2019, Journal of molecular biology.

[96]  Nick C Fox,et al.  Familial Alzheimer’s disease patient-derived neurons reveal distinct mutation-specific effects on amyloid-beta , 2019, Molecular Psychiatry.

[97]  M. Amiot,et al.  CSF1R and BTK inhibitions as novel strategies to disrupt the dialog between mantle cell lymphoma and macrophages , 2019, Leukemia.

[98]  Hiromasa Hashimoto,et al.  Optimization of an azetidine series as inhibitors of colony stimulating factor-1 receptor (CSF-1R) Type II to lead to the clinical candidate JTE-952. , 2019, Bioorganic & medicinal chemistry letters.

[99]  A. Scherz,et al.  Potentiating vascular-targeted photodynamic therapy through CSF-1R modulation of myeloid cells in a preclinical model of prostate cancer , 2019, Oncoimmunology.

[100]  Ye Tian,et al.  Colony-stimulating factor 1 receptor inhibition blocks macrophage infiltration and endometrial cancer cell proliferation , 2019, Molecular medicine reports.

[101]  Ted Laderas,et al.  CSF1R inhibitors exhibit antitumor activity in acute myeloid leukemia by blocking paracrine signals from support cells. , 2019, Blood.

[102]  Shannon E Niedermeyer,et al.  Respiratory Failure in Amyotrophic Lateral Sclerosis , 2019, Chest.

[103]  S. Appel,et al.  Immune dysregulation in amyotrophic lateral sclerosis: mechanisms and emerging therapies , 2019, The Lancet Neurology.

[104]  Young Hoon Kim,et al.  Synthesis and evaluation of thieno[3,2-d]pyrimidine derivatives as novel FMS inhibitors. , 2019, Bioorganic & medicinal chemistry letters.

[105]  Ki Duk Park,et al.  First-in-class DAPK1/CSF1R dual inhibitors: Discovery of 3,5-dimethoxy-N-(4-(4-methoxyphenoxy)-2-((6-morpholinopyridin-3-yl)amino)pyrimidin-5-yl)benzamide as a potential anti-tauopathies agent. , 2019, European journal of medicinal chemistry.

[106]  J. Correale,et al.  Microglial modulation through colony‐stimulating factor‐1 receptor inhibition attenuates demyelination , 2018, Glia.

[107]  M. Filippi,et al.  Multiple sclerosis , 2018, Nature Reviews Disease Primers.

[108]  B. Lamb,et al.  Inflammation as a central mechanism in Alzheimer's disease , 2018, Alzheimer's & dementia.

[109]  R. Singh,et al.  Recent advances in colony stimulating factor-1 receptor/c-FMS as an emerging target for various therapeutic implications. , 2018, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[110]  S. Sen,et al.  CSF-1/CSF-1R axis is associated with epithelial/mesenchymal hybrid phenotype in epithelial-like inflammatory breast cancer , 2018, Scientific Reports.

[111]  M. Białasek,et al.  Evaluation of phenotypic and functional stability of RAW 264.7 cell line through serial passages , 2018, PloS one.

[112]  N. Gray,et al.  Kinase inhibitors: the road ahead , 2018, Nature Reviews Drug Discovery.

[113]  Wilfried Frieauff,et al.  Brain region-specific enhancement of remyelination and prevention of demyelination by the CSF1R kinase inhibitor BLZ945 , 2018, Acta Neuropathologica Communications.

[114]  G. Robert,et al.  IL-34 and CSF-1 display an equivalent macrophage differentiation ability but a different polarization potential , 2018, Scientific Reports.

[115]  M. El-Gamal,et al.  Recent Advances of Colony-Stimulating Factor-1 Receptor (CSF-1R) Kinase and Its Inhibitors. , 2018, Journal of medicinal chemistry.

[116]  M. El-Gamal,et al.  Pyrrolo[3,2-c]pyridine derivatives with potential inhibitory effect against FMS kinase: in vitro biological studies , 2018, Journal of enzyme inhibition and medicinal chemistry.

[117]  J. Mordoh,et al.  Immunomodulatory Monoclonal Antibodies in Combined Immunotherapy Trials for Cutaneous Melanoma , 2017, Front. Immunol..

[118]  D. Hume,et al.  Transcriptional mechanisms that control expression of the macrophage colony-stimulating factor receptor locus. , 2017, Clinical science.

[119]  V. Prachayasittikul,et al.  Roles of Pyridine and Pyrimidine Derivatives as Privileged Scaffolds in Anticancer Agents. , 2017, Mini reviews in medicinal chemistry.

[120]  L. Peyrin-Biroulet,et al.  Crohn's disease , 2017, The Lancet.

[121]  Feng Zhou,et al.  Sulfatinib, a novel kinase inhibitor, in patients with advanced solid tumors: results from a phase I study , 2017, Oncotarget.

[122]  J. Correale,et al.  Progressive multiple sclerosis: from pathogenic mechanisms to treatment. , 2016, Brain : a journal of neurology.

[123]  Y. Kataoka,et al.  High Potency VEGFRs/MET/FMS Triple Blockade by TAS-115 Concomitantly Suppresses Tumor Progression and Bone Destruction in Tumor-Induced Bone Disease Model with Lung Carcinoma Cells , 2016, PloS one.

[124]  B. Strooper,et al.  Alzheimer's Disease Mechanisms and Emerging Roads to Novel Therapeutics , 2016 .

[125]  J. Maher,et al.  Role of the colony-stimulating factor (CSF)/CSF-1 receptor axis in cancer. , 2016, Biochemical Society transactions.

[126]  P. Tak,et al.  Colony-stimulating factor (CSF) 1 receptor blockade reduces inflammation in human and murine models of rheumatoid arthritis , 2016, Arthritis Research & Therapy.

[127]  Gregory W. Kauffman,et al.  Strategies toward optimization of the metabolism of a series of serotonin-4 partial agonists: investigation of azetidines as piperidine isosteres , 2016, Xenobiotica; the fate of foreign compounds in biological systems.

[128]  Mariana Vargas-Caballero,et al.  Pharmacological targeting of CSF1R inhibits microglial proliferation and prevents the progression of Alzheimer’s-like pathology , 2016, Brain : a journal of neurology.

[129]  A. Kühl,et al.  Diversity of Intestinal Macrophages in Inflammatory Bowel Diseases , 2015, Front. Immunol..

[130]  B. L. Caputto,et al.  c-Fos importance for brain development , 2015, Aging.

[131]  Eliezer J. Barreiro,et al.  Chapter 1:Privileged Scaffolds in Medicinal Chemistry: An Introduction , 2015 .

[132]  B. West,et al.  Targeting the colony stimulating factor 1 receptor alleviates two forms of Charcot-Marie-Tooth disease in mice. , 2015, Brain : a journal of neurology.

[133]  P. Sharma,et al.  The future of immune checkpoint therapy , 2015, Science.

[134]  Rimma Berenstein.  Class III Receptor Tyrosine Kinases in Acute Leukemia – Biological Functions and Modern Laboratory Analysis , 2015, Biomarker insights.

[135]  J. Mes,et al.  THP-1 cell line: an in vitro cell model for immune modulation approach. , 2014, International immunopharmacology.

[136]  G. Bánhegyi,et al.  Physiological functions of presenilins; beyond γ-secretase. , 2014, Current pharmaceutical biotechnology.

[137]  E. Stanley,et al.  CSF-1 receptor signaling in myeloid cells. , 2014, Cold Spring Harbor perspectives in biology.

[138]  J. Parsons,et al.  Epidemiology and etiology of benign prostatic hyperplasia and bladder outlet obstruction , 2014, Indian journal of urology : IJU : journal of the Urological Society of India.

[139]  S. Plevy,et al.  The Role of Macrophages and Dendritic Cells in the Initiation of Inflammation in IBD , 2014, Inflammatory bowel diseases.

[140]  Christina S. Leslie,et al.  CSF-1R inhibition alters macrophage polarization and blocks glioma progression , 2013, Nature Medicine.

[141]  R. Head,et al.  Transcriptional profiling and pathway analysis of CSF-1 and IL-34 effects on human monocyte differentiation. , 2013, Cytokine.

[142]  Y. Li,et al.  Degeneration and impaired regeneration of gray matter oligodendrocytes in amyotrophic lateral sclerosis , 2013, Nature Neuroscience.

[143]  V. Perry,et al.  Regulation of Microglial Proliferation during Chronic Neurodegeneration , 2013, The Journal of Neuroscience.

[144]  J. Relton,et al.  Colony-stimulating factor 1 receptor (CSF1R) signaling in injured neurons facilitates protection and survival , 2013, The Journal of experimental medicine.

[145]  W. Sandborn,et al.  Crohn's disease , 2012, The Lancet.

[146]  Simon J. Henderson,et al.  Monoclonal antibody therapeutics: history and future. , 2012, Current opinion in pharmacology.

[147]  K. Paruch,et al.  Cyclin-dependent kinase inhibitors inspired by roscovitine: purine bioisosteres. , 2012, Current pharmaceutical design.

[148]  Ø. Hovde,et al.  Epidemiology and clinical course of Crohn's disease: results from observational studies. , 2012, World journal of gastroenterology.

[149]  L. Coussens,et al.  Differential macrophage programming in the tumor microenvironment. , 2012, Trends in immunology.

[150]  P. Abrams,et al.  Worldwide prevalence estimates of lower urinary tract symptoms, overactive bladder, urinary incontinence and bladder outlet obstruction , 2011, BJU international.

[151]  R. Appelberg,et al.  Macrophages from IBD patients exhibit defective tumour necrosis factor-α secretion but otherwise normal or augmented pro-inflammatory responses to infection. , 2011, Immunobiology.

[152]  E. Campo,et al.  Molecular pathogenesis of mantle cell lymphoma: new perspectives and challenges with clinical implications. , 2011, Seminars in hematology.

[153]  A. Prakash,et al.  Dual inhibition: a novel promising pharmacological approach for different disease conditions , 2011, The Journal of pharmacy and pharmacology.

[154]  N. Meanwell.  Synopsis of some recent tactical application of bioisosteres in drug design. , 2011, Journal of medicinal chemistry.

[155]  D. Schadendorf,et al.  Improved survival with ipilimumab in patients with metastatic melanoma. , 2010, The New England journal of medicine.

[156]  J. Corradi,et al.  Phospholipidosis as a function of basicity, lipophilicity, and volume of distribution of compounds. , 2010, Chemical research in toxicology.

[157]  A. Lusis,et al.  Targeting distinct tumor-infiltrating myeloid cells by inhibiting CSF-1 receptor: combating tumor evasion of antiangiogenic therapy. , 2010, Blood.

[158]  S. Chambers.  Role of CSF-1 in progression of epithelial ovarian cancer. , 2009, Future oncology.

[159]  Y. Gorin,et al.  Colony-stimulating factor-1 (CSF-1) directly inhibits receptor activator of nuclear factor-{kappa}B ligand (RANKL) expression by osteoblasts. , 2009, Endocrinology.

[160]  G. Hortobagyi,et al.  Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Reverses Mesenchymal to Epithelial Phenotype and Inhibits Metastasis in Inflammatory Breast Cancer , 2009, Clinical Cancer Research.

[161]  Jian Sun,et al.  [Study on correlation between connective tissue growth factor, macrophage colony-stimulating factor and cartilage degeneration in the osteoarthritis chondrocytes]. , 2009, Zhongguo gu shang = China journal of orthopaedics and traumatology.

[162]  B. Porse,et al.  Bone Marrow-Derived Macrophages (BMM): Isolation and Applications. , 2008, CSH protocols.

[163]  P. Allavena,et al.  Macrophage polarization in tumour progression. , 2008, Seminars in cancer biology.

[164]  C. Busch,et al.  The prognostic impact of M‐CSF, CSF‐1 receptor, CD68 and CD3 in prostatic carcinoma , 2008, Histopathology.

[165]  Brendan F Boyce,et al.  Biology of RANK, RANKL, and osteoprotegerin , 2007, Arthritis research & therapy.

[166]  D. Maraganore,et al.  A Genomic Pathway Approach to a Complex Disease: Axon Guidance and Parkinson Disease , 2007, PLoS genetics.

[167]  N. K. Williams,et al.  The 2.7 A crystal structure of the autoinhibited human c-Fms kinase domain. , 2007, Journal of molecular biology.

[168]  R. Sartor.  Mechanisms of Disease: pathogenesis of Crohn's disease and ulcerative colitis , 2006, Nature Clinical Practice Gastroenterology &Hepatology.

[169]  L. Moran,et al.  Transcriptome analysis reveals link between proteasomal and mitochondrial pathways in Parkinson’s disease , 2006, Neurogenetics.

[170]  J. Pollard,et al.  Distinct role of macrophages in different tumor microenvironments. , 2006, Cancer research.

[171]  L. Moran,et al.  Whole genome expression profiling of the medial and lateral substantia nigra in Parkinson’s disease , 2006, Neurogenetics.

[172]  J. Parham,et al.  Inhibition of colony-stimulating-factor-1 signaling in vivo with the orally bioavailable cFMS kinase inhibitor GW2580. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[173]  Connie Phong,et al.  Microglia Overexpressing the Macrophage Colony-Stimulating Factor Receptor Are Neuroprotective in a Microglial-Hippocampal Organotypic Coculture System , 2005, The Journal of Neuroscience.

[174]  T. Itokawa,et al.  CSF-1 Induces fos Gene Transcription and Activates the Transcription Factor Elk-1 in Mature Osteoclasts , 2005, Calcified Tissue International.

[175]  N. Osborne,et al.  Retinal ischemia: mechanisms of damage and potential therapeutic strategies , 2004, Progress in Retinal and Eye Research.

[176]  S. Cummings,et al.  Epidemiology and outcomes of osteoporotic fractures , 2002, The Lancet.

[177]  U. Studer,et al.  Osteopontin: possible role in prostate cancer progression. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[178]  R. Angeletti,et al.  Protein tyrosine phosphatase-1C is rapidly phosphorylated in tyrosine in macrophages in response to colony stimulating factor-1. , 1992, The Journal of biological chemistry.

[179]  T. Pawson,et al.  Tyr721 regulates specific binding of the CSF‐1 receptor kinase insert to PI 3′‐kinase SH2 domains: a model for SH2‐mediated receptor‐target interactions. , 1992, The EMBO journal.

[180]  R. Hoffmann,et al.  Hydrogen bonding in pyridine , 1968 .

[181]  G. S. Singh.  Advances in synthesis and chemistry of azetidines , 2020, Advances in Heterocyclic Chemistry.

[182]  R. Mach,et al.  Development of brain PET imaging agents: Strategies for imaging neuroinflammation in Alzheimer's disease. , 2019, Progress in molecular biology and translational science.

[183]  Hiromasa Hashimoto,et al.  Discovery of a novel azetidine scaffold for colony stimulating factor-1 receptor (CSF-1R) Type II inhibitors by the use of docking models. , 2019, Bioorganic & medicinal chemistry letters.

[184]  N. M. Raghavendra,et al.  Dual or multi-targeting inhibitors: The next generation anticancer agents. , 2018, European journal of medicinal chemistry.

[185]  A. Stepan,et al.  Synthesis and Biopharmaceutical Evaluation of Imatinib Analogues Featuring Unusual Structural Motifs , 2016, ChemMedChem.

[186]  Xiang-Shu Cheng,et al.  Phosphorylation of tau by death-associated protein kinase 1 antagonizes the kinase-induced cell apoptosis. , 2013, Journal of Alzheimer's disease : JAD.

[187]  R. Castellani,et al.  Alzheimer disease. , 2010, Disease-a-month : DM.

[188]  Corinna Weber-Schöndorfer.  2.12 – Immunomodulators , 2007 .

[189]  Jan Kelder,et al.  Use of physicochemical calculation of pKa and CLogP to predict phospholipidosis-inducing potential: a case study with structurally related piperazines. , 2004, Experimental and toxicologic pathology : official journal of the Gesellschaft fur Toxikologische Pathologie.